LENSAR Upgraded to Buy Rating by Lake Street Capital

Analysts see potential 62% upside for the medical technology company.

Apr. 1, 2026 at 1:42pm

Got story updates? Submit your updates here. ›

LENSAR (NASDAQ:LNSR), a medical technology company specializing in advanced laser systems for ophthalmic surgery, was upgraded from a 'hold' rating to a 'buy' rating by Lake Street Capital. The firm also set a $10.00 price target for the company, indicating a potential upside of 61.94% from the previous closing price.

Why it matters

The upgrade and price target increase from Lake Street Capital suggest that analysts see significant growth potential for LENSAR, a company that has focused its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment procedures.

The details

In a research report issued on Wednesday, Lake Street Capital raised its rating on LENSAR from 'hold' to 'buy' and set a $10.00 price target for the company. This price target represents a potential upside of 61.94% from LENSAR's previous closing price. Several other equity analysts have also weighed in on LENSAR, with BTIG Research upgrading the stock to 'buy' and Weiss Ratings reissuing a 'sell (d-)' rating.

  • LENSAR stock opened at $6.18 on Wednesday.
  • The company's 50-day moving average price is $10.70, and its 200-day moving average price is $11.26.

The players

Lake Street Capital

A financial services firm that provides research, trading, and investment banking services.

LENSAR

A medical technology company specializing in advanced laser systems for ophthalmic surgery, headquartered in Orlando, Florida.

Got photos? Submit your photos here. ›

The takeaway

The upgrade and increased price target from Lake Street Capital suggest that analysts see significant growth potential for LENSAR, a company that has focused its efforts on improving surgical accuracy and patient outcomes in the cataract treatment market.